Janet Hopkins
Net worth: 426 362 $ as of 2026-06-29
Net worth: 426 362 $ as of 2026-06-29
Janet Jill Hopkins is Director at Gyroscope Therapeutics Holdings Plc since 2022 and Chief Medical Officer at Aura Biosciences, Inc. since 2023.
Former roles include Chief Executive Officer at Gyroscope Therapeutics Ltd. from 2021 to 2023 and SVP, Global Head-Ophthalmology & Exploratory at Novartis AG from 2021 to 2023.
Education includes a doctorate from McMaster University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AURA BIOSCIENCES INC 0.06% | 2026-05-31 | 60,051 ( 0.06% ) | 426 362 $ | 2026-06-29 |
| Companies | Position | Start |
|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Director/Board Member | 2022-02-16 |
| AURA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2023-10-15 |
| Companies | Position | End |
|---|---|---|
| NOVARTIS AG | Corporate Officer/Principal | 2023-09-30 |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Develops gene therapies and medicines for eye diseases | Chief Executive Officer | 2023-09-30 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Aura Biosciences, Inc.
Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
Novartis AG
Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
McMaster University
McMaster University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Develops gene therapies and medicines for eye diseases | Health Technology |
Gyroscope Therapeutics Holdings Plc
Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Develops clinical-stage gene therapies to treat diseases of eyes | Health Technology |
Select your edition
All financial news and data tailored to specific country editions